ENTRY       D02995                      Drug
NAME        Asenapine maleate (JAN/USAN);
            Saphris (TN)
PRODUCT     SAPHRIS (Allergan)
  GENERIC   ASENAPINE (Alembic Pharmaceuticals Limited)
            ASENAPINE (Alembic Pharmaceuticals)
            ASENAPINE (Breckenridge Pharmaceutical)
            ASENAPINE (Greenstone LLC)
            ASENAPINE (MSN LABORATORIES PRIVATE LIMITED)
            ASENAPINE (Sigmapharm Laboratories)
FORMULA     C17H16ClNO. C4H4O4
EXACT_MASS  401.103
MOL_WEIGHT  401.8402
CLASS       Neuropsychiatric agent
             DG01478  Dopamine antagonist
              DG01474  Dopamine D2-receptor antagonist
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
            Metabolizing enzyme inhibitor
             DG01645  CYP2D6 inhibitor
REMARK      Therapeutic category: 1179
            ATC code: N05AH05
            Chemical structure group: DG03100
            Product (DG03100): D11769<US> D02995<JP/US>
EFFICACY    Antipsychotic
  DISEASE   Schizophrenia [DS:H01649]
            Bipolar I disorder [DS:H01653]
COMMENT     Treatment of psychosis
TARGET      HTR1A [HSA:3350] [KO:K04153]
            HTR2A [HSA:3356] [KO:K04157]
            HTR2C [HSA:3358] [KO:K04157]
            HTR6 [HSA:3362] [KO:K04162]
            HTR7 [HSA:3363] [KO:K04163]
            DRD2 [HSA:1813] [KO:K04145]
  PATHWAY   hsa04080(1813+3350+3356+3358+3362+3363)  Neuroactive ligand-receptor interaction
            hsa04726(3350+3356+3358+3362+3363)  Serotonergic synapse
            hsa04728(1813)  Dopaminergic synapse
METABOLISM  Enzyme: CYP1A2 [HSA:1544]
INTERACTION CYP inhibition: CYP2D6 [HSA:1565]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N05 PSYCHOLEPTICS
               N05A ANTIPSYCHOTICS
                N05AH Diazepines, oxazepines, thiazepines and oxepines
                 N05AH05 Asenapine
                  D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antipsychotics
              2nd Generation/Atypical
               Asenapine
                D02995  Asenapine maleate (JAN/USAN)
             Bipolar Agents
              Bipolar Agents, Other
               Asenapine
                D02995  Asenapine maleate (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               117  Psychotropics
                1179  Others
                 D02995  Asenapine maleate (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01478  Dopamine antagonist
               DG01474  Dopamine D2-receptor antagonist
                DG03100  Asenapine
                 D02995  Asenapine maleate
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG03100  Asenapine
                D02995  Asenapine maleate
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               DG03100  Asenapine
                D02995  Asenapine maleate
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Dopamine
                DRD2
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
               Serotonin
                HTR1A
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
                HTR2A
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
                HTR2C
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
                HTR6
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
                HTR7
                 D02995  Asenapine maleate (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D02995
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02995
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02995
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D02995
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D02995
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01478  Dopamine antagonist
               DG01474  Dopamine D2-receptor antagonist
                DG03100  Asenapine
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG03100  Asenapine
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               DG03100  Asenapine
DBLINKS     CAS: 85650-56-2
            PubChem: 17397151
            ChEBI: 71245
            LigandBox: D02995
            NIKKAJI: J349.614G
ATOM        28
            1   C8y C    13.9474  -15.0494
            2   C1y C    14.8548  -16.0964
            3   C1y C    16.2507  -16.0964
            4   C8y C    17.0882  -14.9797
            5   C8y C    14.2267  -13.6535
            6   C8y C    16.7392  -13.6535
            7   O2x O    15.4829  -13.0254
            8   C8x C    17.7861  -12.6764
            9   C8x C    19.1123  -13.0254
            10  C8x C    19.4612  -14.4213
            11  C8x C    18.4143  -15.3984
            12  C8x C    12.6214  -15.4682
            13  C8y C    11.5744  -14.5608
            14  C8x C    11.8536  -13.1650
            15  C8x C    13.1798  -12.7462
            16  C1x C    16.7392  -17.4224
            17  N1y N    15.6225  -18.2600
            18  C1x C    14.4360  -17.4224
            19  X   Cl   10.2483  -14.9797
            20  C1a C    15.6225  -19.6559
            21  O6a O    21.2759  -16.2359
            22  C6a C    22.6019  -16.2359
            23  O6a O    23.2999  -17.3526
            24  C2b C    23.2999  -15.0494
            25  C2b C    24.9052  -15.0494
            26  C6a C    25.6032  -16.2359
            27  O6a O    26.9990  -16.2359
            28  O6a O    24.9750  -17.4224
BOND        30
            1     3   4 1
            2     1   5 1
            3     4   6 1
            4     2   3 1
            5     5   7 1
            6     1   2 1
            7     6   7 1
            8     6   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12    4  11 2
            13    1  12 2
            14   12  13 1
            15   13  14 2
            16   14  15 1
            17    5  15 2
            18    3  16 1
            19   16  17 1
            20   17  18 1
            21    2  18 1
            22   13  19 1
            23   17  20 1
            24   21  22 1
            25   22  23 2
            26   22  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   26  28 1
///
